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Overview of Canine Babesiosis
Poonam Vishwakarma and M.K. Nandini
Abstract
Canine babesiosis is a tick-borne, protozoal, haemoparasitic disease that can 
cause varying degrees of haemolytic anaemia, splenomegaly, thrombocytopenia 
and fever. There are two hosts for the transmission of Babesia spp., viz. invertebrate 
(tick) and vertebrate host. Dogs are one among the many targets of Babesia spp., 
causing canine babesiosis, and now there are clinical evidences of possible vertical 
transmission too. Dogs of all ages can be affected with Babesia spp., but young pup-
pies are more commonly affected. Considering advanced diagnostic techniques, for 
an early and specific detection of acute infections, an AgELISA that is potentially 
translatable to a rapid diagnostic test design is reported. Different molecular tech-
niques used for identification and differentiation of the various species of Babesia 
are semi-nested PCR, reverse line blotting and PCR-restriction fragment length 
polymorphism analysis. Treatment consists of three components: treatment with 
antiprotozoal agents to eliminate the parasite, blood transfusions to treat severe 
anaemia and supportive care for the complications and metabolic derangements. 
Blood lactate concentrations can serve as a prognostic indicator in severe or compli-
cated canine babesiosis. For prevention apart from conventional measures, vaccines 
against Babesia species such as B. gibsoni are currently being developed.
Keywords: haemolytic anaemia, babesiosis, reverse line blotting, intraerythrocytic, 
blood lactate, semi-nested PCR
1. Introduction
Canine babesiosis is a clinically significant tick-borne disease caused by api-
complexan parasites of the genus Babesia which has been reported worldwide 
including India. These verity of the disease depends on multiple factors such as the 
type of Babesia species involved, the age and the immune status of the host [1, 2]. It 
is caused by different Babesia species with a worldwide distribution characterised 
by erythrocyte destruction causing mild to severe systemic clinical manifestations 
[3] like varying degrees of haemolytic anaemia, splenomegaly, thrombocytopenia 
and fever.
2. Classification
Babesia organisms are frequently classified as large or small. Historically, Babesia 
spp. in dogs was identified by their morphological appearance in erythrocytes 
of blood smears (intraerythrocytic merozoite stage). Initially, all large forms 
measuring between 3 and 5 μm were classified as B. canis, whereas all small forms 
measuring 1–3 μm were designated as B. gibsoni, but molecular analysis and DNA 
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sequencing have revealed that there are at least three small piroplasms infecting 
dogs, viz. B. gibsoni, B. conradae and the recently reported “Babesia vulpes” [4].
In former times, on the basis of cross immunity, serological testing, vector speci-
ficity and molecular phylogeny, Babesia canis was categorised into three subspecies 
(B. canis canis, B. canis rossi, B. canis vogeli) [5, 6], but now these subspecies are 
considered as separate species [7, 8].
3. Prevalence
Out of three previously considered subspecies, Babesia rossi is the most virulent 
species and occurs predominantly in southern Africa. Babesia vogeli is the least 
pathogenic species occurring in France, Australia, Japan, Brazil, South Africa and 
the USA and usually causes mild disease in adult dogs but severe disease in some 
puppies [9]. Babesia canis is of intermediate pathogenicity and is widespread in 
Europe and Asia.
B. gibsoni, the smaller piroplasm is prevalent mainly in the Middle East, southern 
Asia, Japan, North Africa and South America and is an emerging infectious disease 
in the USA, as well as having been detected lately in Italy, Hungary and Australia 
[10]. A more virulent subspecies of B. gibsoni has also been identified in California 
[11]. Babesia microti-like piroplasma, B. annae (also known as Theileria annae), has 
been found to be endemic in dogs in northwest Spain [12]. In India both B. canis 
[13, 14] and B. gibsoni [15, 16] are prevalent, and almost all states of the country are 
affected.
4. Zoonotic importance
Babesia species affecting dogs and/or cats are not reported to be of zoonotic 
importance [17]. However, dogs and cats are close companions of people and can 
serve as a source of infected ticks for humans [18]. Human babesiosis is a rare dis-
ease and primarily involves just two species of Babesia: Babesia divergens, a parasite 
of cattle in Europe, and Babesia microti that parasitizes small rodents in the USA.
5. Transmission
There are two hosts for transmission of Babesia spp., viz., invertebrate (tick) 
and vertebrate host. Dogs are one among the many targets of Babesia spp., causing 
canine babesiosis (formerly called canine piroplasmosis).
Hard ticks are the main vectors for Babesia spp. Species such as Rhipicephalus 
sanguineus, Dermacentor spp. and Haemaphysalis ellipticum can transmit the large 
Babesia of dogs, whereas B. gibsoni is transmitted by Haemaphysalis bispinosa and 
Haemaphysalis longicornis. Babesia annae is thought to be transmitted by Ixodes 
hexagonus [19]. Both trans-stadial and transovarial transmissions can occur, and 
ticks are believed to remain infective for several generations.
Babesia spp. undergoes the sexual conjugation and the sporogony portions of 
their life cycles inside the lumen of the intestine and then within the haemocoel 
of the tick. Then the sporozoites from the tick’s salivary gland are transmitted to 
their new vertebrate host via a blood meal, and thereafter the protozoan life cycle is 
completed within the red blood cells by asexual replication (merogony), where the 
parasites appear as merozoites [20], which leaves the host cell and enters another 
red blood cell. This cycle continues for the entire life tenure of vertebrate host or 
3Overview of Canine Babesiosis
DOI: http://dx.doi.org/10.5772/intechopen.82243
until the host’s immune system terminates the process. However, in many countries 
for the last one decade, Babesia gibsoni infections have been reported in the absence 
of tick vectors. There is now convincing evidence that these cases have arisen due 
to biting and fighting between infected and noninfected dogs [21, 22], but these 
parasites are primarily transmitted through tick bites. This association arose as a 
by-product of the tick’s adaptation to feed on blood.
The first clinical evidence of possible vertical transmission has been docu-
mented for B. canis [23] and B. microti-like spp. [24]. Although Babesia undergoes 
part of their life cycles in ticks, the merozoites circulating in the blood may be 
transmitted to a healthy host directly by blood transfusion. This scenario has been 
described for B. gibsoni infection [25] and by direct contact between dogs through 
wounds (fighting dogs), saliva or blood ingestion [21, 22, 26].
6. Clinical signs and pathogenesis
Dogs of all ages can be affected with Babesia spp., but young puppies are more 
commonly affected. The incubation period varies from 10 to 21 days for B. canis and 
14–28 days for B. gibsoni. Mortality for Babesia spp. infections ranges from 12% for 
B. rossi to approximately 1% for B. vogeli [19].
The most predominant feature of babesiosis in infected dogs are haemolytic 
anaemia and thrombocytopenia. Multiple causes like extra- and intravascular 
haemolysis, RBC destruction due to increased osmotic fragility, shortened life span 
of RBCs, erythrophagocytosis and immune-mediated destruction of RBCs because 
of parasitic antigens, parasite-induced membrane damage and possibly other 
membrane-associated antigens leads to anaemia [27–29]. Impaired haemoglobin 
function, oxidative damage, sludging and sequestration of erythrocytes also likely 
occur [27, 28, 30].
Recent study revealed about the renal involvement in babesiosis. Hypoxaemia, 
glomerulonephritis and haemoglobinuric nephropathy are considered possible 
mechanisms and supported by histological studies [31].
Pancreatitis is frequently associated with other complications and has a mortal-
ity rate of 20%. Common finding includes vomition, melaena, icterus, abdominal 
pain and diarrhoea. In addition, 65% of the dogs with pancreatitis also had icterus, 
30% had acute respiratory distress syndrome (ARDS), 30% had immune-mediated 
red blood cell destruction (IMHA), and 15% had acute renal failure (ARF), while 
10% had haemoconcentration, and another 10% had cerebral syndrome. It is postu-
lated that pancreatitis is formerly described “gut” form of babesiosis [32].
The severe form of disease is characterised by marked haemolytic anaemia and 
acid–base abnormalities [33] with secondary multiple organ failure and complica-
tions such as ARF, hepatopathy, hypoglycaemia [34], ARDS, IMHA and cerebral 
pathology [35]. Small subset of dogs presents with high haematocrits (relative 
haemoconcentration), despite vigorous haemolysis, due to shifting of fluid from 
intravascular to extravascular component. These dogs are at increased risk of 
developing ARF or cerebral complications, as well as other organ failures [36].
The severity of the disease depends on the species of Babesia, presence of 
concurrent infections, age and immune status of the host. The disease presentation 
varies widely from peracute to chronic or even subclinical. Babesia rossi, the domi-
nant species found in South Africa, is very virulent and causes peracute and acute 
disease. Most common signs include fever, anorexia, weakness, depression, pale 
mucous membranes, tachycardia, tachypnoea and splenomegaly. Clinical signs are 
because of tissue hypoxia following anaemia and a concomitant systemic inflamma-
tory response syndrome caused by marked cytokine release [19].
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Babesia vogeli causes clinically inapparent infection in mature dogs. The para-
sitaemia is very low, and infection may be missed while routine examination of 
blood smear. Subclinical infections are common in adult dogs, but puppies tend to 
present with marked anaemia [37]. It is endemic in greyhound kennels in the USA, 
and particular care should be taken when relocating greyhounds that can harbour 
subclinical infections.
Babesia canis infections result in a more variable pathogenicity, intermediate 
between B. rossi and B.vogeli. Anaemia is reported in majority of dogs and thrombo-
cytopenia in all cases [38].
Babesia gibsoni infection follows either hyperacute, acute or chronic course. 
Among these acute course is the most common and is characterised by fever, leth-
argy, haemolytic anaemia, thrombocytopenia, lymphadenopathy and splenomegaly 
[39]. The hyperacute state is rare and is characterised by shock and extensive tissue 
damage. Mostly a disease of American Pit Bull and Staffordshire Bull Terriers is 
transmitted via dog bites [21]. In Australia and the USA, subclinical B. gibsoni infec-
tions have been reported, where they are PCR positive, but neither show clinical 
illness nor microscopic parasitaemia [40]. Such cases can have dire consequences if 
imported into non-endemic areas.
Babesia conradae is considered to be more pathogenic than B. gibsoni, resulting in 
higher parasitaemias and more severe anaemia [11].
6.1 Cardiac dysfunction
It’s a rare complication of canine babesiosis; reported macroscopic cardiac 
lesions are effusions in pericardium, epicardial and endocardial haemorrhage 
involving one or more chambers with left ventricle being most commonly affected. 
Histopathological changes include necrosis, haemorrhage, fibrin micro-thrombi in 
the myocardium and inflammation. Lesions may be multifocal, but more generally 
they are limited to one area within the myocardium [41].
6.2 Consequence of canine babesiosis
Complicated babesiosis involves clinical manifestations that are not related 
to haemolytic disease. The most commonly documented complications include 
coagulopathy, ARF, ARDS, icterus and hepatopathy, haemoconcentration, immune-
mediated haemolytic anaemia (IMHA), pancreatitis, hypotension, myocardial 
pathology, cerebral babesiosis and shock. Rare complications include gastrointesti-
nal disturbance, myalgia, ocular involvement, upper respiratory signs, necrosis of 
the extremities and fluid accumulation. These complications can overlap.
7. Diagnosis
A precise and fast diagnosis and prompt treatment is required in critical situa-
tions such as hyperacute to acute phase of B. canis infection, where high mortality is 
generally reported.
7.1 Direct (microscopic) examination
Historically, Babesia infection in dogs was identified based on the morphologic 
appearance of the parasite in the erythrocyte; thus, microscopic evaluation for 
detecting intraerythrocytic parasites in Giemsa or Wright’s stained blood smears 
remains the simplest, most accessible and reasonably sensitive especially during 
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acute infections. Differentiation between large and small piroplasms is also rela-
tively simple. Moreover, in many parts of the developing world where babesiosis 
is endemic, microscopy is still the only viable available option. The likelihood of 
spotting a piroplasm increases with proper sampling technique, viz. sampling from 
capillary beds (ear tip, toe nail) or examination of cells from beneath the buffy coat 
of a haematocrit tube [37, 42] or search along the periphery of the blood smear, as 
parasitized red blood cells tend to marginate while making the smear. For diagnosis 
of large forms of Babesia (e.g. B. canis) from the majority of sick dogs, light micros-
copy is highly specific [2, 43], but small piroplasms (B. gibsoni, B. microti-like sp.) 
are hard to observe by light microscopy, which has a relatively poor to moderate 
sensitivity [44], and expertise is needed. Moreover due to very low, often intermit-
tent parasitaemias, identification of piroplasms in chronically infected and carrier 
dogs remains a significant challenge.
Diagnosis is more problematic in chronic cases of infection due to less virulent 
species such as B. canis and B. vogeli, where parasitaemia may be below the micro-
scopic detection limit, and in such cases thick smears (not alcohol fixed) may be 
helpful in detecting the parasite.
7.2 Haematological changes
The major haematological changes include mild to moderately regenerative 
normocytic and normochromic anaemia, leucocytosis with normal to decreased 
neutrophil counts and most consistent finding thrombocytopenia which is severe in 
the acute phase of infection [45].
7.3 Coagulation profiles
In a recent study, it was reported that there is significantly lower mean platelet 
count, prolonged activated partial thromboplastin time, higher fibrinogen concen-
trations and D-dimer value in infected dogs as compared to healthy controls [46].
7.4 Biochemical abnormalities
Elevation of liver enzymes such as ALP, ALT and AST. Elevated serum bilirubin 
concentration is associated with degree and rapidity of the anaemia and accompa-
nying hepatopathy. There will be low total serum protein and albumin level in dogs 
with babesiosis. Urea is disproportionately raised to creatinine, and this is probably 
due to increased urea production resulting from gastrointestinal haemorrhage or 
protein catabolism as a result of febrile inflammatory illness [47, 48]. In complicated 
cases with renal dysfunction, there will be proportionate increase in serum urea and 
creatinine levels indicating decreased renal perfusion, as a result of hypovolaemia, 
decreased blood pressure and/or decreased myocardial function. Hypokalaemia 
has been reported in severely affected dog, it has not connected directly with 
babesiosis, and this could be attributed to decreased potassium intake. Considerable 
elevation of positive acute phase protein (α1-acid glycoprotein) has been reported 
in dogs with B. rossi infection, but levels do not correlate with severity of disease or 
outcome [49].
7.5 Metabolic abnormalities
The most common complication is hypoglycaemia and is often associated with 
severe anaemia, icterus, young age (<6 months) and collapse [50]. Reduced sur-
vival has been associated with hypoglycaemia (<59.4 mg/dL) and hyperlactataemia. 
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Hypoglycaemia-induced central nervous system signs should not be misdiagnosed 
as cerebral babesiosis.
7.6 Electrocardiogram (ECG findings)
In canine babesiosis, variety of arrhythmias are reported including sinus arrest, 
sinoatrial block, first- and second-degree atrioventricular block, ventricular 
tachycardia and ventricular premature depolarizations. ECG abnormalities include 
prolonged QRS interval, low amplitude and notching of R waves, ST segment 
deviation and large T waves [41].
7.7 Urine analysis
Routine test may reveal presence of bilirubin, haemoglobin and protein in the 
urine. In a recent study conducted to assess renal dysfunction in Babesia rossi, 
infection revealed higher concentrations of urinary IgG, urinary CRP and urinary 
RBP suggestive of both glomerular and tubular dysfunction [51]. These can be 
used for early detection of Babesia-induced renal dysfunction than serum urea and 
creatinine and urine specific gravity. There will be minimum and variable changes 
in urine enzyme activity (GGT and ALP) in babesiosis, thus limiting their use as 
diagnostic tests [47].
7.8 Serological diagnosis
A recent study demonstrated the opportunity of an early and specific detection 
of acute infections by an AgELISA that is potentially translatable to a rapid diag-
nostic test design and can be used in an ELISA to detect circulating Babesia antigen 
during acute infections and can be used to detect parasites 24–48 h before it could 
be detected by light microscopy [52].
7.9 Molecular diagnosis
Molecular techniques help in refining the diagnosis to the species level and thus 
provide a more accurate prognosis. Different molecular techniques are used for 
identification and differentiation of the various species of Babesia, semi-nested 
PCR [53] reverse line blotting [9, 54] and PCR-restriction fragment length poly-
morphism analysis [55].
Improved PCR techniques have lately allowed for better definition of these 
parasites [56] and allows for a more reliable identification of the etiological agents 
compared to direct detection by light microscopy or serology [2]. It is more sensitive 
and provides an evidence of an active and ongoing infection in a clinical setting.
In addition, several genes are commonly used to discriminate among Babesia 
species. Typically, these include the nuclear ribosomal RNA genes [7, 8] and the two 
internal transcribed spacers (ITS1 and ITS2) [7]. PCR DNA amplification can be a 
useful technique for monitoring treatment [57].
7.10 Diagnostic imaging
The most consistent findings on abdominal ultrasonography in dogs with B. 
canis are hepatomegaly and splenomegaly with diffuse, hypoechoic, heterogene-
ity and renal changes like diffuse homogenous increased cortical echogenicity 
and increased corticomedullary definition [58]. Dogs infected with B. rossi and 
B. canis having gastrointestinal signs and abdominal pain are reported to have 
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ultrasonographic changes in the pancreases [32, 59] which are found to be consis-
tent with acute pancreatitis and included duodenal atony and peripancreatic fat 
hyperechogenicity.
7.11 Differential diagnosis
It includes other causes of haemolytic anaemia such as haemobartonellosis, 
autoimmune haemolytic anaemia, pyruvate kinase deficiency and Heinz body hae-
molytic anaemia. Other differentials include immune-mediated thrombocytopenia, 
systemic lupus erythematosus, leptospirosis, rickettsial diseases, dirofilariasis with 
caval syndrome, leptospirosis, zinc toxicity and neoplasia.
8. Therapy
Treatment for canine babesiosis consists of three components:
• Treatment to eliminate the parasite
• Blood transfusions to treat severe anaemia
• Supportive care for the complications and metabolic derangements
8.1  Main drugs and drug combinations used in the antiprotozoal treatment  
of babesiosis
a. Imidocarb dipropionate: It is an aromatic diamidine and is recommended to be 
used as 6.6 mg/kg intramuscularly (IM) or subcutaneously (SC) with a repeated 
dose in 2 weeks in dogs. Among many of the proposed mechanisms of action 
includes blockage of the entry of inositol into erythrocytes containing Babesia, 
resulting in starvation of the parasite [60], interference with production [61] or 
combination with DNA in susceptible Babesia species, causing nucleic acid damage 
and inhibition of cellular repair and replication [62] (Table 1). It is approved for 
treatment of different forms of Babesia spp. [39, 57, 63]. The adverse effects of this 
medication include pain during injection and cholinergic effects such as salivation, 
drooling, nasal drip or vomiting which can be mitigated by premedicating with 
atropine at 0.05 mg/kg. Additionally some less frequent adverse effects are panting, 
restlessness, diarrhoea, renal tubular or hepatic necrosis and injection site inflam-
mation and more rarely ulceration, which usually heals within days to weeks.
b. Diminazene aceturate: It is 4,4′-(diazoamino) dibenzamidine diaceturate 
which is widely used in tropical countries as a first-line agent for the treat-
ment of Babesia gibsoni infection of dogs, usually as an intramuscular injection 
of 3.5 mg/kg. Although diminazene aceturate has anti-Babesia activity, it 
often fails to eliminate B. gibsoni from affected dogs and a relapse may occur. 
Furthermore, diminazene has a narrow clinical safety margin and can induce 
fatal nervous complications after 24–48 h of overdose. Clinical signs associated 
with diminazene toxicity are depression or stupor, continuous vocalisation, 
ataxia, opisthotonos, extensor rigidity, nystagmus and seizures [3]. There are 
reported toxicity such as acute CNS signs including ataxia, nystagmus and 
occasional seizures in dogs administered with one recommended intramuscu-
lar dose (3.5 mg/kg) of diminazene for treatment of babesiosis [64].
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8.2 Combination therapies
a. Atovaquone and azithromycin: The first treatment that has been shown to 
be effective against B. gibsoni is a combination of an analog of ubiquinone, 
atovaquone (ATV) and a macrolide antibiotic, azithromycin (AZM) [57]. The 
use of ATV alone inhibits the growth of Babesia spp. and is presumed to act 
through blocking protozoan mitochondrial electron transport causing inhibi-
tion of pyrimidine and ATP synthesis [62]. Azithromycin acts by inhibiting 
the translation of mRNA and bacterial protein synthesis by binding to the 
50S subunit of the prokaryote ribosome. It exerts its antiprotozoal effects by 
specifically acting on apicoplasts, a non-photosynthetic plastid organelles with 
a limited genome and found in apicomplexan parasites [65] including Babesia 
spp. [66]. In addition, the simultaneous use of ATV and AZM produces an 
additive or synergistic therapeutic effect, while the single use of each drug 
tends to result in a relapse of signs. Moreover possible emergence of drug-
resistant variants of B. gibsoni can occur after the use of ATV alone, and these 
variants might be caused by mutations in the cytochrome b (CYTb) gene, 
resulting in amino acid substitutions at the putative ATV binding site [67]. 
Further, the results are not consistent based on molecular analysis [68].
b. Buparvaquone and azithromycin: Buparvaquone is a hydroxynaphthoqui-
none antiprotozoal drug-related to atovaquone and parvaquone. Buparvaquone 
(Butalex®) is used in the treatment of bovine theileriosis [69]. It is also used to 
treat B. vulpes infection in dogs at an off-label dose of 5 mg/kg IM twice 48 h 
apart, in combination with azithromycin at 10 mg/kgPO once daily for 10 days 
[63]. Buparvaquone’s mode of action on piroplasms is probably comparable to 
atovaquone’s.
c. Combination therapy of clindamycin (CLDM), metronidazole (MNZ) and 
doxycycline (DOXY) is an efficacious alternative treatment strategy for B. 
gibsoni infection [70]. However, this treatment takes a relatively long time to 
show its therapeutic effect [71].
Babesia 
species
Drug Dose and duration Response to treatment
B. canis,  
B. vogeli and 
B. rossi
Imidocarb 
dipropionate
5–6.6 mg/kg IM once; 
may repeat in 14 days
Good
Diminazene 
aceturate
A single dose of 3.5 mg/kg
B. gibsoni Azithromycin + 
atovaquone
10 mg/kg PO
SID + 13.3 mg/kg PO TID 
for10 days
Improvement of anaemia and 
clinical signs without elimination 
of parasite and with occasional to 
frequent clinical relapses
Clindamycin 12–25 mg/kg PO BID for 
7–10 days
B. conradae Imidocarb 
dipropionate
5–6.6 mg/kg IM once; 
may repeat in 14 days
Moderate to poor with frequent 
relapses
B. microti-like Imidocarb 
dipropionate
5–6.6 mg/kg IM once; 
may repeat in 14 days
Poor
Table 1. 
Summary of the treatment protocols with antiprotozoal agents.
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8.3 Supportive treatment
Supportive therapy should be based on thorough patient assessment and should 
be provided for moderate-to-severe infection depending on the type of Babesia spp. 
infecting the dog which may include:
a. Fluid therapy: In Babesia-infected dogs, intravenous fluid therapy is required 
for patients in shock, old dogs with history of renal disease, clinically dehydrated 
patients and dogs with intravascular haemolysis and haemoglobinuria. Mildly dehy-
drated patients (approximately 5%) require 50 ml/kg body weight, and moderately 
dehydrated (approximately 10%) requires 100 ml/kg body weight, whereas severely 
dehydrated (15%) dogs require about 150 ml/kg body weight of replacement fluid. 
Usually intravenous crystalloid fluid is indicated with correction of electrolyte and 
acid–base abnormalities. It is important to maintain blood volume and adequate 
end-organ perfusion diuresis and prevention of red blood cell sludging in capillar-
ies [72]. Hetastarch (10 to 20 ml/kg) causes greater plasma volumes expansion, its 
beneficial in resuscitative fluid therapy. As fluid therapy can exacerbate ARDS, close 
monitoring of respiratory rate and pulmonary sounds is crucial.
b. Whole blood/ RBC/plasma transfusion: Need for blood transfusion depends 
on magnitude of anaemia (haematocrit ≤15%) and clinical signs such as 
dyspnoea or tachypnoea. The degree of parasitaemia is not an important factor 
as it often bears little relation to the degree of anaemia. Packed erythrocytes 
(20 mL/kg) are the component of choice for treating haemolytic anaemia. 
Crossmatching is not mandatory for the first transfusion, as dogs do not have 
naturally occurring alloantibodies. Initially blood is transfused slowly at 2 ml/
kg/h for the first 30–60 min while observing for transfusion reactions, such as 
a sudden rise in body temperature and/or respiratory rate and lip and ear pinna 
swelling. Infected dogs with disseminated intravascular coagulation or coagu-
lation disorders may require plasma transfusions.
c. Immunosuppressants: The use of immunosuppressant drugs in dogs with 
immune-mediated haemolytic anaemia (IMHA) or thrombocytopenia is 
controversial because these conditions are always associated with infectious 
disease. But in cases of unresponsiveness to antiprotozoal treatment, the use of 
2 mg/kg/day of prednisone is recommended in infected dogs with moderate-
to-severe clinical signs [73].
d. Other supportive therapies: Other supportive therapies depend on the clinical 
signs and/or laboratory abnormalities, for example, oxygen therapy should be 
used when there is respiratory distress and antiemetics to counter vomiting. If 
the dog is stable and does not require hospitalization, then treatment should be 
restricted to antiprotozoal agents [74].
9. Prognostic indicators
In a recent study, it was suggested that lactate as a prognostic indicator with 
mean lactate in complicated cases of canine babesiosis wherein the blood lactate 
concentration in non-survivors (145 mg/dL) was higher than in survivors (13.8 mg/
dL). Pretreatment hyperlactataemia (>45 mg/dL) and subsequent serial lactate 
concentrations that failed to return to normal reference range (persistently >40 mg/
dL) indicate poor prognosis [75].
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10. Prevention
The most effective preventive measures practised worldwide are regular control 
of the tick vectors by routinely dipping or spraying pets or using tick collars or 
spot-on preparations. As it takes a minimum of 48 hours for Babesia transmis-
sion, so regular examination of dogs for the presence of any ticks and to remove it 
soon after they attach is important. The merozoites circulating in the blood may 
be transmitted to a healthy host directly by blood transfusion, so blood donors 
should be screened negative for babesiosis, preferably by polymerase chain reac-
tion. Moreover, it is also reported that B. gibsoni can be transmitted by transfer 
of blood during dog fighting, which should be prevented. In Europe a vaccine is 
available against B. canis with a reported efficacy of 70–100% [76]. More recently 
a bivalent vaccine called Pirodog® (Merial) derived from soluble parasite antigens 
from B. canis and B. rossi obtained from culture media supernatant has been shown 
to reduce duration and severity of clinical signs [77]. Although vaccination against 
canine babesiosis does not prevent infection, it does seem to block the initiation of 
pathologic processes involved in the pathogenesis of the disease [78]. This vaccine 
can be administered from 5 months of age and requires annual revaccination but 
does not cross-protect against other Babesia species. Vaccines against other Babesia 
species such as B. gibsoni are currently being developed including recombinant 
antigen and DNA vaccines [79–81]. Although dogs can be vaccinated, the level of 
protection is highly variable, which might be due to genetic diversity of B. canis 
strains.
11. Conclusion
The spectrum of Babesia pathogens that infect dogs is gradually being elucidated 
with the aid of new molecular techniques and meticulous clinical investigation. 
Species of Babesia that cannot be distinguished morphologically cause diverse 
diseases and are transmitted by different vector ticks. Nonvector transmission by 
blood transfusion and directly from dog to dog is of special concern and could be 
responsible for the spread of infection to areas that were previously non-endemic. 
Correctly identifying the infectious agent is important for treatment planning and 
prognosis.
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